Details of the Drug

General Information of Drug (ID: DMBUOUV)

Drug Name

ASP1570

Indication

Disease Entry	ICD 11	Status	REF
Aggressive cancer	2A00-2F9Z	Phase 1/2	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecule

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Diacylglycerol kinase zeta (DGKZ)	TTSBBXL	DGKZ_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT05083481) A Phase 1/2 Study of ASP1570 as Monotherapy and in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors. U.S.National Institutes of Health.
2	Manipulation of diacylglycerol and ERK-mediated signaling differentially controls CD8(+) T cell responses during chronic viral infection. Front Immunol. 2022 Nov 24;13:1032113.